Sonnet BioTherapeutics (SONN) Registration Filing summary

Company overview and business model

• Clinical-stage, oncology-focused biotech with a proprietary FHAB™ platform for single- and bifunctional biologic medicines targeting solid tumors and other diseases.

• Lead asset SON-1010 (IL-12-FHAB) in Phase 1/1b/2a trials for solid tumors and platinum-resistant ovarian cancer; additional pipeline includes SON-080 (IL-6) for neuropathies and SON-1210 (IL12-FHAB-IL15) for solid tumors.

• Business model leverages strategic outsourcing, cost-advantaged clinical sites, and licensing partnerships to optimize R&D spend and accelerate development.

Financial performance and metrics

• Net loss of $4.3M for the nine months ended June 30, 2024, down from $15.2M in the prior year period; accumulated deficit of $114.6M as of June 30, 2024.

• Cash balance of $3.6M at June 30, 2024, with substantial doubt about ability to continue as a going concern beyond November 2024 without additional financing.

• Research and development expenses decreased to $4.5M for the nine months ended June 30, 2024, reflecting cost-saving initiatives and program prioritization.

• Collaboration revenue recognized from licensing agreements, including $18,626 in the nine months ended June 30, 2024.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.4M from the offering, intended for R&D (including clinical trials), working capital, repayment of liabilities, and general corporate purposes.

• Proceeds will be allocated based on evolving business needs, with flexibility to adjust as additional financing or partnership opportunities arise.